- Home
- IFRX vs INVE Comparison
IFRX vs INVE Comparison
Compare IFRX & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- INVE
- Stock Information
- Founded
- IFRX 2007
- INVE 1990
- Country
- IFRX Germany
- INVE United States
- Employees
- IFRX N/A
- INVE N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- INVE Computer peripheral equipment
- Sector
- IFRX Health Care
- INVE Technology
- Exchange
- IFRX Nasdaq
- INVE Nasdaq
- Market Cap
- IFRX 86.0M
- INVE 85.9M
- IPO Year
- IFRX 2017
- INVE 1997
- Fundamental
- Price
- IFRX $1.77
- INVE $3.70
- Analyst Decision
- IFRX Strong Buy
- INVE Strong Buy
- Analyst Count
- IFRX 5
- INVE 2
- Target Price
- IFRX $9.80
- INVE $5.50
- AVG Volume (30 Days)
- IFRX 6.9M
- INVE 50.4K
- Earning Date
- IFRX 11-07-2025
- INVE 11-10-2025
- Dividend Yield
- IFRX N/A
- INVE N/A
- EPS Growth
- IFRX N/A
- INVE N/A
- EPS
- IFRX N/A
- INVE N/A
- Revenue
- IFRX $73,729.00
- INVE $22,015,000.00
- Revenue This Year
- IFRX N/A
- INVE N/A
- Revenue Next Year
- IFRX $1,216.24
- INVE $9.06
- P/E Ratio
- IFRX N/A
- INVE N/A
- Revenue Growth
- IFRX N/A
- INVE N/A
- 52 Week Low
- IFRX $0.71
- INVE $2.86
- 52 Week High
- IFRX $2.82
- INVE $4.29
- Technical
- Relative Strength Index (RSI)
- IFRX 63.15
- INVE 50.11
- Support Level
- IFRX $1.16
- INVE $3.61
- Resistance Level
- IFRX $1.48
- INVE $4.00
- Average True Range (ATR)
- IFRX 0.20
- INVE 0.21
- MACD
- IFRX 0.02
- INVE -0.01
- Stochastic Oscillator
- IFRX 75.64
- INVE 41.94
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.